# Reen-agr Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reen-agr-biotechnology

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.whgrnsw.com
- Latest round: Angel (Jan 17, 2024)
- Investors on record: 3

## About

Founded in 2019 and based in Wuhan, China, Wuhan Green Long Biotechnology Co., Ltd., trading under the name Reen-agr Biotechnology, provides bacteriophage-based biological products and technical solutions for antimicrobial control. The company established in-house research platforms covering bacteriophage discovery, engineering, production, and application, and collaborates with academic institutions including Huazhong Agricultural University. Its products and services are supplied to customers across animal health, crop protection, food safety, and selected medical segments. In December 2025, the firm closed a pre-series B funding round led by new investor Guosen H&S, with participation from new investor TigerYeah Capital.

The company's main business is the research and development, production, and popularization of alternative formulations of antibiotics for animals. It develops its products such as disinfectants, phages, plant extracts, probiotics, and new acid formulations.

The company generates revenue by developing alternative formulations to antibiotics for animals.

The company plans to strengthen its AI-enabled research platform, expand development of engineered bacteriophages and phage-derived products, and broaden commercialization across animal health, crop protection, food safety, and consumer healthcare markets.

## Funding rounds

- Angel, Jan 17, 2024 — CDH Investments, CD Capital
- Angel, Sep 26, 2023 — Zhengxuan Capital

## Investors

- Zhengxuan Capital (https://capitalatlas.ai/funds/zhengxuan-capital) — Angel
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Angel
- CD Capital — Angel